SCHEMBL25167828

SCHEMBL25167828

O=C(O)c1cc(-c2ccccc2)cc(=O)o1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.53
KMT2A Q03164 1/20 0.53
HPGD P15428 2/20 0.50
ALDH1A1 P00352 1/20 0.50
USP2 O75604 1/20 0.47
CSNK2A2 P19784 1/20 0.47
PTGS1 P23219 1/20 0.47
CSNK2B P67870 1/20 0.47
CSNK2A1 P68400 1/20 0.47
CSNK2A3 Q8NEV1 1/20 0.47
PTGER4 P35408 6/20 0.46
EGFR P00533 1/20 0.42
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
KMO O15229 1/20 0.41
GLA P06280 1/20 0.41
MAPT P10636 1/20 0.41
TSHR P16473 1/20 0.41
HTT P42858 1/20 0.41
HSD17B10 Q99714 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31016027 0.87 KDM4E (0.49) KDM4EKMT2AHPGDALDH1A1USP2
SCHEMBL25417800 0.87 KDM4E (0.49) KDM4EKMT2AHPGDALDH1A1USP2
SCHEMBL30314634 0.85 DHODH (0.46) KDM4EKMT2AHPGDALDH1A1NPC1
SCHEMBL25174183 0.81 MAPT (0.58) KDM4EKMT2AHPGDALDH1A1EGFR
SCHEMBL6703548 0.76 NPC1 (0.46) KMT2AALDH1A1PTGER4NPC1RAB9A
SCHEMBL8366506 0.74 PRKDC (0.51) KDM4EKMT2AHPGDALDH1A1NPC1
SCHEMBL25174059 0.73 KDM4E (0.49) KDM4EKMT2AHPGDUSP2CSNK2A2
SCHEMBL25167846 0.73 RAB9A (0.49) KDM4EKMT2AHPGDALDH1A1USP2
SCHEMBL3737353 0.72 PTGER4 (0.57) HPGDALDH1A1PTGS1PTGER4EGFR
SCHEMBL9322052 0.72 CTRC (0.46) KDM4EKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250002487-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF VENTUS THERAPEUTICS U.S., INC. (US) 2025-01-02 US disclosed
EP-4436968-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF Ventus Therapeutics U.S., Inc. (US) 2024-10-02 EP disclosed
CN-118201924-A Heterocyclic compounds and their use 万特斯治疗美国公司 2024-06-14 CN disclosed
WO-2023081441-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF VENTUS THERAPEUTICS U.S., INC. (US) 2023-05-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250002487-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF CGAS, TDP1, CYP11B2 KDM4E 4732/4885KMT2A 4398/4885HPGD 516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.